Pediatric acute lymphoblastic leukemia, version 2.2020

Patrick Brown; Hiroto Inaba; Colleen Annesley; Jill Beck; Susan Colace; Mari Dallas; Kenneth DeSantes; Kara Kelly; Carrie Kitko; Norman Lacayo; Nicole Larrier; Luke Maese; Kris Mahadeo; Ronica Nanda; Valentina Nardi; Vilmarie Rodriguez; Jenna Rossoff; Laura Schuettpelz; Lewis Silverman; Jessica Sun; Weili Sun; David Teachey; Victor Wong; Gregory Yanik; Alyse Johnson-Chilla; Ndiya Ogba

doi:10.6004/jnccn.2020.0001

Pediatric acute lymphoblastic leukemia, version 2.2020

Patrick Brown, Hiroto Inaba, Colleen Annesley, Jill Beck, Susan Colace, Mari Dallas, Kenneth DeSantes, Kara Kelly, Carrie Kitko, Norman Lacayo, Nicole Larrier, Luke Maese, Kris Mahadeo, Ronica Nanda, Valentina Nardi, Vilmarie Rodriguez, Jenna Rossoff, Laura Schuettpelz, Lewis Silverman, Jessica SunWeili Sun, David Teachey, Victor Wong, Gregory Yanik, Alyse Johnson-Chilla, Ndiya Ogba

Research output: Contribution to journal › Review article › peer-review

114 Scopus citations

Abstract

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved survival rates. However, additional clinical management is needed to improve outcomes for patients classified as high risk at presentation (eg, T-ALL, infant ALL) and who experience relapse. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for pediatric ALL provide recommendations on the workup, diagnostic evaluation, and treatment of the disease, including guidance on supportive care, hematopoietic stem cell transplantation, and pharmacogenomics. This portion of the NCCN Guidelines focuses on the frontline and relapsed/refractory management of pediatric ALL.

Original language	English
Pages (from-to)	81-112
Number of pages	32
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	18
Issue number	1
DOIs	https://doi.org/10.6004/jnccn.2020.0001
State	Published - 2020

Access to Document

10.6004/jnccn.2020.0001

Cite this

Brown, P., Inaba, H., Annesley, C., Beck, J., Colace, S., Dallas, M., DeSantes, K., Kelly, K., Kitko, C., Lacayo, N., Larrier, N., Maese, L., Mahadeo, K., Nanda, R., Nardi, V., Rodriguez, V., Rossoff, J., Schuettpelz, L., Silverman, L., ... Ogba, N. (2020). Pediatric acute lymphoblastic leukemia, version 2.2020. JNCCN Journal of the National Comprehensive Cancer Network, 18(1), 81-112. https://doi.org/10.6004/jnccn.2020.0001

@article{be908a8396e3444fa14207420a749607,

title = "Pediatric acute lymphoblastic leukemia, version 2.2020",

abstract = "Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved survival rates. However, additional clinical management is needed to improve outcomes for patients classified as high risk at presentation (eg, T-ALL, infant ALL) and who experience relapse. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for pediatric ALL provide recommendations on the workup, diagnostic evaluation, and treatment of the disease, including guidance on supportive care, hematopoietic stem cell transplantation, and pharmacogenomics. This portion of the NCCN Guidelines focuses on the frontline and relapsed/refractory management of pediatric ALL.",

author = "Patrick Brown and Hiroto Inaba and Colleen Annesley and Jill Beck and Susan Colace and Mari Dallas and Kenneth DeSantes and Kara Kelly and Carrie Kitko and Norman Lacayo and Nicole Larrier and Luke Maese and Kris Mahadeo and Ronica Nanda and Valentina Nardi and Vilmarie Rodriguez and Jenna Rossoff and Laura Schuettpelz and Lewis Silverman and Jessica Sun and Weili Sun and David Teachey and Victor Wong and Gregory Yanik and Alyse Johnson-Chilla and Ndiya Ogba",

year = "2020",

doi = "10.6004/jnccn.2020.0001",

language = "English",

volume = "18",

pages = "81--112",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "1",

}

Brown, P, Inaba, H, Annesley, C, Beck, J, Colace, S, Dallas, M, DeSantes, K, Kelly, K, Kitko, C, Lacayo, N, Larrier, N, Maese, L, Mahadeo, K, Nanda, R, Nardi, V, Rodriguez, V, Rossoff, J, Schuettpelz, L, Silverman, L, Sun, J, Sun, W, Teachey, D, Wong, V, Yanik, G, Johnson-Chilla, A & Ogba, N 2020, 'Pediatric acute lymphoblastic leukemia, version 2.2020', JNCCN Journal of the National Comprehensive Cancer Network, vol. 18, no. 1, pp. 81-112. https://doi.org/10.6004/jnccn.2020.0001

TY - JOUR

T1 - Pediatric acute lymphoblastic leukemia, version 2.2020

AU - Brown, Patrick

AU - Inaba, Hiroto

AU - Annesley, Colleen

AU - Beck, Jill

AU - Colace, Susan

AU - Dallas, Mari

AU - DeSantes, Kenneth

AU - Kelly, Kara

AU - Kitko, Carrie

AU - Lacayo, Norman

AU - Larrier, Nicole

AU - Maese, Luke

AU - Mahadeo, Kris

AU - Nanda, Ronica

AU - Nardi, Valentina

AU - Rodriguez, Vilmarie

AU - Rossoff, Jenna

AU - Schuettpelz, Laura

AU - Silverman, Lewis

AU - Sun, Jessica

AU - Sun, Weili

AU - Teachey, David

AU - Wong, Victor

AU - Yanik, Gregory

AU - Johnson-Chilla, Alyse

AU - Ogba, Ndiya

PY - 2020

Y1 - 2020

N2 - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved survival rates. However, additional clinical management is needed to improve outcomes for patients classified as high risk at presentation (eg, T-ALL, infant ALL) and who experience relapse. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for pediatric ALL provide recommendations on the workup, diagnostic evaluation, and treatment of the disease, including guidance on supportive care, hematopoietic stem cell transplantation, and pharmacogenomics. This portion of the NCCN Guidelines focuses on the frontline and relapsed/refractory management of pediatric ALL.

AB - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved survival rates. However, additional clinical management is needed to improve outcomes for patients classified as high risk at presentation (eg, T-ALL, infant ALL) and who experience relapse. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for pediatric ALL provide recommendations on the workup, diagnostic evaluation, and treatment of the disease, including guidance on supportive care, hematopoietic stem cell transplantation, and pharmacogenomics. This portion of the NCCN Guidelines focuses on the frontline and relapsed/refractory management of pediatric ALL.

UR - http://www.scopus.com/inward/record.url?scp=85077709236&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2020.0001

DO - 10.6004/jnccn.2020.0001

M3 - Review article

C2 - 31910389

AN - SCOPUS:85077709236

SN - 1540-1405

VL - 18

SP - 81

EP - 112

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 1

ER -

Pediatric acute lymphoblastic leukemia, version 2.2020

Abstract

Access to Document

Other files and links

Fingerprint

Cite this